AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

AstraZeneca (AZN) announced that the FDA had approved Voydeya (danicopan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and chronic blood disorder.Voydeya is a first-in-class oral Factor D inhibitor, which has been approved by the FDA as an add-on to standard-of-care C5 inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab), for the treatment of extravascular hemolysis in adult patients with PNH. Ultomiris and Soliris are also marketed by AstraZeneca for treating PNH and some other rar ...